___________________
Penetrating and interfering peptides for the treatment of cancer
This project is based on the modeling, characterization and development of new therapeutic tools for the treatment of cancers, pathologies requiring the development of specific therapies without side effects.

To this end, we are using the approach of penetrating peptides and tumor interfering peptides (TP and IP), capable of specifically penetrating the tumor cell, with no effect on healthy cells, and blocking the interaction between two proteins deregulated during tumor transformation. We are also developing organelle-specific penetrating peptides focusing on the nucleus and mitochondria.
The cell-penetrating and cell-interfering peptide approach has great relevance in medicine, with over 240 therapeutic peptides currently being tested in clinical trials. What’s more, a large number have already been approved for the treatment of several pathologies. This project is highly relevant to the field of oncology, and original in terms of the approach used to identify protein-protein interactions and optimize drug candidates.
___________________
Also to be read

Job offer : Two-year Postdoctoral Position. Project: FunkNano4Cancer – Functionalisation of nanoparticles for improved diagnostics and anti-cancer efficacy
Job offer : Two-year Postdoctoral Position. Project: FunkNano4Cancer – Functionalisation of nanoparticles for improved diagnostics and anti-cancer efficacy.

1st meeting on Lipid Nanoparticles for delivery
Nathalie Mignet and her team, in association with the Société Française de Nanomédecine, are organizing the 1st meeting on Lipid Nanoparticles for RNA delivery on Thursday April 3, 2025 at the Faculté de Pharmacie in Paris.

Nathalie Mignet, at the “advances in nanomedicine” international conference
The international conference “advances in nanomedicine” organized by the editorial office of the journal Precision Nanomedecine and the Kalinga Institute in Bhubaneswar, Odisha, India, brought together the leading names in nanomedicine, Lou Balogh, editor-in-chief of...

Sarah Diakhaby, at the 6th International Cancer Symposium of the CRCL
Sarah Diakhaby shared part of her PhD work during the 6th International Cancer Symposium of the CRCL.